Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers

Diabetes Care

Volumn 32, Issue 8, 2009, Pages 1485-1490

  Konoshita, Tadashi ^a   Kato, Norihiro ^b   Fuchs, Śebastien ^c   Mizuno, Shinichi ^a   Aoyama, Chikako ^a   Motomura, Makoto ^a   Makino, Yasukazu ^a   Wakahara, Shigeyuki ^a   Inoki, Isao ^a   Miyamori, Isamu ^a   Pinet, Florence ^d  

^a University of Fukui   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE; THYMINE; VALSARTAN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERTENSION; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REN GENE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; BODY MASS INDEX; CREATININE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DNA PRIMERS; FEMALE; GENE DELETION; GENETIC VARIATION; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 68149136741     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-0348     Document Type: Article

References (25)

1. Corvol P, Soubrier F, Jeunemaitre X. Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension. Pathol Biol (Paris) 1997;45:229-239 (Pubitemid 27207336)
2. Wakahara S, Konoshita T, Mizuno S, Motomura M, Aoyama C, Makino Y, Kato N, Koni I, Miyamori I. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology 2007; 148:2453-2457 (Pubitemid 46997072)
3. Konoshita T, Wakahara S, Mizuno S, Motomura M, Aoyama C, Makino Y, Kawai Y, Kato N, Koni I, Miyamori I, Mabuchi H. Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 2006;29:848-852 (Pubitemid 44115305)
4. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensinconverting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641-644
5. Konoshita T, Miyagi K, Onoe T, Katano K, Mutoh H, Nomura H, Koni I, Miyamori I, Mabuchi H. Effect of ACE gene polymorphism on age at renal death in polycystic kidney disease in Japan. Am J Kidney Dis 2001;37:113-118 (Pubitemid 32055026)
6. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Pierre C. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992;71:169-180
7. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-69 (Pubitemid 24195405)
8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869 (Pubitemid 34940825)
9. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031 (Pubitemid 38781102)
10. Farahani P, Dolovich L, Levine M. Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension. J Clin Epidemiol 2007;60:1-7 (Pubitemid 44856235)
11. Fuchs S, Philippe J, Germain S, Mathieu F, Jeunemaitre X, Corvol P, Pinet F. Functionality of two new polymorphisms in the human renin gene enhancer region. J Hypertens 2002;20:2391-2398 (Pubitemid 36026851)
12. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acid Res 1992;20:1433
13. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH. A prospective evaluation of an angiotensin- convertingenzyme gene polymorphism and the risk of ischemic heart disease [see comments]. N Engl J Med 1995;332:706-711
14. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark AJ. Linkage of the angiotensinogen gene to essential hypertension [see comments]. N Engl J Med 1994;330:1629-1633 (Pubitemid 24166862)
15. Katsuya T, Horiuchi M, Minami S, Koike G, Santoro NF, Hsueh AJ, Dzau VJ. Genomic organization and polymorphism of human angiotensin II type 2 receptor: no evidence for its gene mutation in two families of human premature ovarian failure syndrome. Mol Cell Endocrinol 1997;127:221-228
16. Johnson JA, Turner ST. Hypertension pharmacogenomics: current status and future directions. Curr Opin Mol Ther 2005;7:218-225 (Pubitemid 40790544)
17. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvanen AC, Lind L. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004;17:8-13 (Pubitemid 38064752)
18. Redon J, Luque-Otero M, Martell N, Chaves FJ. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005;5:14-20 (Pubitemid 40220612)
19. Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, Shahinfar S, Wong PH, Lyle PA, Rossing P, Brenner BM. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008;19:771-779
20. Konoshita T, Germain S, Philippe J, Corvol P, Pinet F. Evidence that renal and chorionic tissues contain similar nuclear binding proteins that recognize the human renin promoter. Kidney Int 1996;50:1515-1524 (Pubitemid 26364256)
21. Konoshita T, Makino Y, Wakahara S, Ido K, Yoshida M, Kawai Y, Miyamori I. Candidate cis-elements for human renin gene expression in the promoter region. J Cell Biochem 2004;93:327-336
22. Konoshita T, Fuchs S, Makino Y, Wakahara S, Miyamori I. A proximal direct repeat motif characterized as a negative regulatory element in the human renin gene. J Cell Biochem 2007;102:1043-1050 (Pubitemid 350036943)
23. Germain S, Bonnet F, Philippe J, Fuchs S, Corvol P, Pinet F. A novel distal enhancer confers chorionic expression on the human renin gene. J Biol Chem 1998;273: 25292-25300 (Pubitemid 28443295)
24. Fuchs S, Germain S, Philippe J, Corvol P, Pinet F. Expression of renin in large arteries outside the kidney revealed by human renin promoter/LacZ transgenic mouse. Am J Pathol 2002;161:717-725 (Pubitemid 36142180)
25. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109: 1417-1427 (Pubitemid 34596167)